TY - JOUR
T1 - Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer
T2 - Results from the randomized ITACa trial
AU - Gardini, Andrea Casadei
AU - Scarpi, Emanuela
AU - Orlandi, Elena
AU - Tassinari, Davide
AU - Leo, Silvana
AU - Bernardini, Ilaria
AU - Gelsomino, Fabio
AU - Tamberi, Stefano
AU - Ruscelli, Silvia
AU - Vespignani, Roberto
AU - Ronconi, Sonia
AU - Frassineti, Giovanni Luca
AU - Amadori, Dino
AU - Passardi, Alessandro
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Background: The aim of this study was to investigate the role of pre-treatment aspartate aminotransferase-lynphocyte ratio (ALRI) as a predictor of prognosis and treatment efficacy in patients with metastatic colorectal cancer (mCRC) enrolled in the prospective multicenter randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial to receive first-line chemotherapy (CT) + bevacizumab (B) or CT alone. Patients and methods: Patients randomly received CT+B or CT alone as first-line therapy. CT consisted of either FOLFOX4 or FOLFIRI at the clinician’s discretion. Results: Out of the 284 patients enrolled, increased ALRI levels were associated with shorter PFS and OS (p<0.0001). At baseline, median PFS was 10.3 months (95% CI 9.4–12.0) and 8.0 months (95 % CI 6.8–8.9), and median OS was 25.2 months (95 % CI 21.3–30.2) and 18.8 months (95 % CI 16.6–21.7) for patients with low (<14) and high (≥14) ALRI levels, respectively (HR 1.43, 95% CI 1.12–1.82, p=0.004; HR=1.51, 95% CI 1.17–1.96, p<0.001). Interaction tests on ALRI levels and treatment efficacy in the CT+B and the CT groups were statistically significant for PFS (p=0.0003), but not for OS (p=0.228). Conclusion: Our results indicate that ALRI is a good prognostic and predictive marker for mCRC patients candidate for CT+B.
AB - Background: The aim of this study was to investigate the role of pre-treatment aspartate aminotransferase-lynphocyte ratio (ALRI) as a predictor of prognosis and treatment efficacy in patients with metastatic colorectal cancer (mCRC) enrolled in the prospective multicenter randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial to receive first-line chemotherapy (CT) + bevacizumab (B) or CT alone. Patients and methods: Patients randomly received CT+B or CT alone as first-line therapy. CT consisted of either FOLFOX4 or FOLFIRI at the clinician’s discretion. Results: Out of the 284 patients enrolled, increased ALRI levels were associated with shorter PFS and OS (p<0.0001). At baseline, median PFS was 10.3 months (95% CI 9.4–12.0) and 8.0 months (95 % CI 6.8–8.9), and median OS was 25.2 months (95 % CI 21.3–30.2) and 18.8 months (95 % CI 16.6–21.7) for patients with low (<14) and high (≥14) ALRI levels, respectively (HR 1.43, 95% CI 1.12–1.82, p=0.004; HR=1.51, 95% CI 1.17–1.96, p<0.001). Interaction tests on ALRI levels and treatment efficacy in the CT+B and the CT groups were statistically significant for PFS (p=0.0003), but not for OS (p=0.228). Conclusion: Our results indicate that ALRI is a good prognostic and predictive marker for mCRC patients candidate for CT+B.
KW - Aspartate aminotransferase-lymphocyte ratio index
KW - Bevacizumab
KW - Clinical outcome
KW - First line
KW - Metastatic colorectal cancer
KW - Prognosis
KW - Rectal cancer
UR - http://www.scopus.com/inward/record.url?scp=85058699055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058699055&partnerID=8YFLogxK
U2 - 10.2147/OTT.S166614
DO - 10.2147/OTT.S166614
M3 - Article
AN - SCOPUS:85058699055
VL - 11
SP - 5261
EP - 5268
JO - OncoTargets and Therapy
JF - OncoTargets and Therapy
SN - 1178-6930
ER -